A Prospective, Open Phase I Study to Investigate the Tolerability and Efficacy of Administering ALECSAT to Pancreas Cancer Patients
Latest Information Update: 07 Nov 2021
At a glance
- Drugs Cancer vaccine-ALECSAT (Primary)
- Indications Pancreatic cancer
- Focus Adverse reactions
- Sponsors CytoVac
- 25 Feb 2019 Status changed to completed.
- 12 Aug 2015 Planned End Date changed from 1 Mar 2015 to 1 Sep 2015, according to ClinicalTrials.gov
- 22 Apr 2015 Status changed from recruiting to discontinued as per ClinicalTrials.gov record.